Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 34)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Sodium oxybate |
Approved |
Phase 2, Phase 3 |
|
502-85-2 |
23663870 |
Synonyms:
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
NSC-84223
OXYBATE SODIUM
SODIUM OXYBATE
|
SODIUM OXYBUTYRATE
WY-3478
XYREM
|
|
2 |
|
Sodium citrate |
Approved, Investigational |
Phase 2, Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
3 |
|
Histamine |
Approved, Investigational |
Phase 3 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
4 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
5 |
|
Anesthetics, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Anesthetics, General |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Anesthetics |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Citrate |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Histamine phosphate |
|
Phase 3 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
11 |
|
Flumazenil |
Approved |
Phase 1, Phase 2 |
|
78755-81-4 |
3373 |
Synonyms:
[<sup>11</sup>C]flumazenil (PET ligand)
Anexate
Anexate®|Ro15-1788
Anexic acid
FLUMAZENIL
Flumazenilo
Flumazenilum
Flumazepil
Hoffman la roche brand OF flumazenil
Hoffman-la roche brand OF flumazenil
|
Lanexat
MAZICON
RO15-1788
RO-151788
RO-15-1788
RO-151788000
RO-1722
RO-41-8157
Roche brand OF flumazenil
Romazicon
|
|
12 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
6-O-METHYL ERYTHROMYCIN
6-O-Methylerythromycin
6-O-Methylerythromycin a
A-56268
ABBOTT-56268
Biaxin
BIAXIN XL
BIAXIN XL PAC
CAM
CLA
CLARIE XL
CLARITHROMYCIN
CLARITHROMYCIN EXTENDED RELEASE
CLARITHROMYCIN IDENTITY
Clarithromycina
Clarithromycine
|
Clarithromycinum
Claritromicina
CLAROSIP
Clathromycin
FEBZIN XL
KLARICID
KLARICID 500
KLARICID ADULT
KLARICID I.V.
KLARICID PAED
KLARICID XL
MYCIFOR XL
PREVPAC
TE-031
XETININ XL
ZECLAR
|
|
13 |
|
Dextroamphetamine |
Approved, Illicit, Investigational |
Phase 2 |
|
51-64-9, 300-62-9 |
5826 3007 |
Synonyms:
(±)-amphetamine|Amphetamine Sulfate®|DL-amphetamine
(+)-(S)-Amphetamine
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+-)-alpha-Methylphenylethylamine
(+)-alpha-methylphenylethylamine|d-amphetamine|Dexadrine®|dextroamphetamine|Dextrostat®|S(+)amphetamine
(+)-a-Methylphenethylamine
(+)-a-Methylphenylethylamine
(+)-Amphetamine
(+)-phenaminum
(+)-Α-methylphenethylamine
(+)-Α-methylphenylethylamine
(+/-)-benzedrine
(+/-)-beta-phenylisopropylamine
(+/-)-desoxynorephedrine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(AlphaS)-alpha-methylbenzeneethanamine
(AlphaS)-a-methylbenzeneethanamine
(AlphaS)-α-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-(+)-b-Phenylisopropylamine
(S)-(+)-Β-phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-Phenyl-2-propylamine
(S)-alpha-Methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(S)-a-Methylbenzeneethanamine
(S)-Amphetamine
(S)-Α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
[1-(3-Methoxyphenyl)-2-propyl]amine
1-Methyl-2-phenylethylamine
1-Phenyl-2-aminopropane
3-Methoxy-a-methylbenzeneethanamine
3-Methoxyamphetamine
3-Methoxyphenylisopropylamine
Actedron
Adipan
Adzenys
ADZENYS ER
ADZENYS XR-ODT
Allodene
alpha-Methylbenzeneethaneamine
Amfetamin
Amfetamina
Amfetamine
Amfetaminum
Amphetamine
AMPHETAMINE RESIN COMPLEX
Amphetamine sulfate
Amphetamine sulfate (2:1)
Amsustain
Anorexide
Anorexine
Benzebar
Benzedrine
Benzolone
beta-Aminopropylbenzene
beta-Phenylisopropylamin
beta-Phenyl-isopropylamine
Celltech brand OF dextroamphetamine sulfate
Centramina
Curban
D Amphetamine
D Amphetamine sulfate
D-(+)-amphetamine
D-(s)-amphetamine
D-1-Phenyl-2-aminopropan
d-1-Phenyl-2-aminopropan [German]
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-alpha-methylphenethylamine
D-am
D-Amphetamine
D-Amphetamine sulfate
Dephadren
Desamfetamina
Desoxyn
Desoxynorephedrin
Desoxynorephedrine
Dexacaps
Dexadrine
Dexamfetamina
|
Dexamfetamina [inn-spanish]
Dexamfetamine
Dexamfetaminum
Dexamfetaminum [inn-latin]
DEXAMPEX
Dexamphetamine
Dexamphetaminum [inn-latin]
Dexanfetamina
Dexanfetamina [inn-spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
Dextro amphetamine
Dextro amphetamine sulfate
Dextroamphetamine
Dextro-amphetamine
DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine sulfate
Dextro-amphetamine sulfate
DextroStat
DL-1-Phenyl-2-aminopropane
DL-alpha-Methylphenethylamine
DL-Amphetamine
DL-Benzedrine
Dyanavel
DYANAVEL XR
Elastonon
Fenamin
Fenamine
Fenylo-izopropylaminyl
FERNDEX
Finam
GlaxoSmithKline brand OF dextroamphetamine sulfate
Isoamycin
Isoamyne
Isomyn
L Amphetamine
L-Amphetamine
Levo amphetamine
Levoamphetamine
Levo-amphetamine
Mallinckrodt brand OF dextroamphetamine sulfate
Mecodrin
Methampex
Methamphetamine HCL
Miquel brand OF amfetamine sulfate
m-Methoxy-a-methylphenethylamine
m-Methoxyamphetamine
Mydrial
Norephedrane
Novydrine
NSC-27159
NSC-73713
Oktedrin
Ortedrine
Oxydess
Paredrine
Pasadena brand OF dextroamphetamine
Percomon
Phenamine
Phenedrine
Phenopromin
Phenylisopropylamine
Profamina
Propisamine
Psychedrine
rac-(2R)-1-phenylpropan-2-amine
rac-amphetamine
Raphetamine
Rhinalator
S(+)-amphetamine
Shire brand OF dextroamphetamine sulfate
Simpatedrin
Simpatina
Sulfate, amphetamine
Sulfate, dextroamphetamine
Sympamin
Sympamine
Sympatedrine
Thyramine
Vortech brand OF dextroamphetamine sulfate
Weckamine
α-methylbenzeneethaneamine
α-methylphenethylamine
β-aminopropylbenzene
β-phenylisopropylamine
|
|
14 |
|
Dopamine |
Approved |
Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
15 |
|
Modafinil |
Approved, Investigational |
Phase 2 |
|
68693-11-8 |
4236 |
Synonyms:
2-((Diphenylmethyl)sulfinyl)acetamide
2-((R)-(Diphenylmethyl)sulfinyl)acetamide
2-[(Diphenylmethyl)sulphinyl]acetamide
Alertec
Armodafinil
Benzhydrylsulfinylacetamide
CEP-1538
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
CRC-40476
CRL-40476
Dea No. 1680
DEP-1538
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
Modafinil
|
Modafinil [Usan:Inn]
MODAFINIL CIV
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Nuvigil
Provigil
Provigil®
R Modafinil
R-Modafinil
Sparlon
THN102 COMPONENT MODAFINIL
THN-102 COMPONENT MODAFINIL
Vigil
|
|
16 |
|
Pentetrazol |
Experimental, Withdrawn |
Phase 2 |
|
54-95-5 |
|
Synonyms:
1,5-Pentamethylenetetrazole
6,7,8,9-Tetrahydro-5-azepotetrazole
6,7,8,9-Tetrahydro-5H-tetrazolo[1,5-a]azepine
7,8,9,10-Tetrazabicyclo[5.3.0]-8,10-decadiene
a,b-Cyclopentamethylenetetrazole
alpha,beta-Cyclopentamethylenetetrazole
Cardiazol
Cardiazole
Cardifortan
Cardiotonicum
Cardosal
Cardosan
Cenalene-m
Cenazol
Coranormol
Corasol
Coratoline
Corazol
Corazole
Corvasol
Coryvet
|
Deumacard
Diovascole
Gewazol
Kardiazol
Korazol
Korazole
Leptazole
Metrazol
Metrazole
Pentamethylene-1,5-tetrazole
Pentamethylenetetrazole
Pentazol
Pentetrazol
Pentetrazole
Pentetrazolum
Pentylenetetrazol
Pentylenetetrazole
Phrenazol
Ventrazol
Α,β-cyclopentamethylenetetrazole
|
|
17 |
|
Convulsants |
|
Phase 2 |
|
|
|
18 |
|
Antidotes |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
GABA Modulators |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
22 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
23 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
24 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Central Nervous System Stimulants |
|
Phase 2 |
|
|
|
27 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
28 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
29 |
|
Dopamine Uptake Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Adderall |
|
Phase 2 |
|
|
|
31 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
32 |
|
Sympathomimetics |
|
Phase 2 |
|
|
|
33 |
|
Caffeine |
Approved |
|
|
58-08-2 |
2519 |
Synonyms:
1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-TRIMETHYLPURINE-2,6-QUINONE
1,3,7-Trimethylxanthine
137X
1-Methyltheobromine
1-Methyl-theobromine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
7-Methyl theophylline
7-Methyltheophylline
Alert-Pep
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anoquan
Berlin-chemie brand OF caffeine
Bristol-myers squibb brand OF caffeine
Cafamil
CAFCIT
Cafecon
Cafeina
Cafeína
Cafeine
Caféine
Cafergot
Caffedrine
Caffedrine Caplets
Caffein
Caffeine
CAFFEINE MELTING POINT STANDARD
Caffeine Pure
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeinum
Caffine
Cafipel
CFF
Coffein
COFFEINE
Coffeinum
Coffeinum N
Coffeinum purrum
Compound 65
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Durvitan
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA NO. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline brand OF caffeine
Guaranine
Hycomine
Invagesic
|
Invagesic Forte
Keep Alert
Kofein
Koffein
Lanorinal
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura brand OF caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Migergot
Miudol
Monohydrate caffeine
Monomethyl Derivative of Theophylline
Natural Caffeinum
Nix Nap
No doz
Nodaca
No-Doz
NODOZ
NODOZ CAPLETS AND CHEWABLE TABLETS
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
NSC-5036
Organex
Orphengesic
Orphengesic Forte
Passauer brand OF caffeine
Pep-Back
Percoffedrinol N
Percutaféine
Peyona®
Phensal
Pierre fabre brand OF caffeine
PRO-PLUS
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick pep
Quick-pep
QuickPep
Refresh'n
Republic drug brand OF caffeine
Respia
Seid brand OF caffeine
SK 65 Compound
Stim
Synalgos-Dc
Teina
Teína
Thein
Theine
Theobromine ME
Theophylline ME
Thompson brand 1 OF caffeine
Thompson brand 2 OF caffeine
Triad
Ultra Pep-Back
Vivarin
Wake-Up
Wigraine
YEAST-VITE
ZANTHINE
|
|
34 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
|
|
73-31-4 |
896 |
Synonyms:
[<sup>3</sup>H]-melatonin|[<sup>3</sup>H]MLT
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
3-(2-Acetamidoethyl)-5-methoxyindole
5-Methoxy-N-acetyltryptamine
BCI-049
Circadin
Circadin®|MLT
GENERAL NUTRIT
HEALTH AID
HEIDADOUPPI
ICENIA
J5.258B
LIFE EXT
MELAPURE
Melatol
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonine
Mélatonine
Melovine
MLT
|
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
NATROL
NATURE'S BLEND
NATURES BOUNTY
NSC-113928
NSC-56423
QUALITY HEALTH
Regulin
S.GARD
TRAVELAG
VESPRO
VYTALONIN
|
|
Interventional clinical trials:
(show all 45)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension |
Completed |
NCT03533114 |
Phase 3 |
JZP-258;Placebo Oral Solution |
2 |
The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study |
Completed |
NCT03682185 |
Phase 3 |
|
3 |
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia |
Recruiting |
NCT05156047 |
Phase 3 |
Pitolisant Oral Tablet;Placebo oral tablet |
4 |
A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia |
Recruiting |
NCT03597555 |
Phase 2, Phase 3 |
Sodium Oxybate Oral Solution 500 MG/ML;Placebos |
5 |
An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 |
Enrolling by invitation |
NCT05458128 |
Phase 3 |
pitolisant |
6 |
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia |
Unknown status |
NCT03542851 |
Phase 2 |
Pentetrazol (PTZ);Placebo oral capsule |
7 |
A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors |
Completed |
NCT01183312 |
Phase 1, Phase 2 |
Flumazenil |
8 |
Clarithromycin for the Treatment of Hypersomnia |
Completed |
NCT01146600 |
Phase 2 |
Clarithromycin followed by placebo;Placebo then Clarithromycin |
9 |
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 |
Completed |
NCT02512588 |
Phase 2 |
BTD-001;Placebo |
10 |
Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes |
Recruiting |
NCT04026958 |
Phase 2 |
Clarithromycin;Placebo |
11 |
Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines |
Recruiting |
NCT03772314 |
Phase 2 |
Modafinil;Amphetamine-Dextroamphetamine |
12 |
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia |
Completed |
NCT04091438 |
Phase 1 |
TAK-925;TAK-925 Placebo |
13 |
Hypersomnia in Major Depressive Disorder |
Unknown status |
NCT04006834 |
|
|
14 |
Prevalence and Characteristics of Sleep Disturbances Among Psychiatric Inpatients |
Unknown status |
NCT04201392 |
|
|
15 |
Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS. |
Unknown status |
NCT04300166 |
|
|
16 |
Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia |
Completed |
NCT03459300 |
|
|
17 |
Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia. |
Completed |
NCT01926405 |
|
|
18 |
Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial |
Completed |
NCT03904238 |
|
|
19 |
Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 |
Completed |
NCT04634682 |
|
|
20 |
Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia |
Completed |
NCT02913651 |
|
|
21 |
Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation |
Completed |
NCT01719315 |
|
|
22 |
The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol |
Completed |
NCT03356938 |
|
|
23 |
Anesthetic Management of Patients With Chronic Sleep Disorders |
Completed |
NCT04827329 |
|
|
24 |
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS) |
Completed |
NCT02037438 |
|
|
25 |
Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases |
Completed |
NCT01877616 |
|
|
26 |
The Feasibility of a Tailored Music Intervention to Reduce Symptoms of Sleep Disruption in Older Adults With Dementia |
Completed |
NCT04157244 |
|
|
27 |
Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders |
Completed |
NCT00001664 |
|
|
28 |
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment. |
Completed |
NCT00916253 |
|
Modafinil;Placebo |
29 |
The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder |
Completed |
NCT01764035 |
|
|
30 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
31 |
Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia |
Recruiting |
NCT05183464 |
|
|
32 |
Swiss Primary Hypersomnolence and Narcolepsy Cohort Study |
Recruiting |
NCT04330963 |
|
|
33 |
Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry) |
Recruiting |
NCT05321355 |
|
|
34 |
A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study |
Recruiting |
NCT05443373 |
|
|
35 |
Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders |
Active, not recruiting |
NCT03018912 |
|
|
36 |
Idiopathic Hypersomnia - a Retrospective Characterization Study |
Enrolling by invitation |
NCT05150977 |
|
|
37 |
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments |
Enrolling by invitation |
NCT05371483 |
|
|
38 |
Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia |
Not yet recruiting |
NCT05627388 |
|
|
39 |
Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence |
Not yet recruiting |
NCT05615584 |
|
|
40 |
Randomized Control Trial to Compare Patient Outcomes Following Unattended Polysomnography Versus In-lab Polysomnography for Sleep Apnea and Comorbid Sleep Disorders |
Not yet recruiting |
NCT05230394 |
|
|
41 |
Disrupted Sleep in the Elderly: Light Exposure Studies |
Suspended |
NCT00427323 |
|
|
42 |
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' |
Suspended |
NCT04419792 |
|
|
43 |
Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy |
Terminated |
NCT03198156 |
|
|
44 |
Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease |
Terminated |
NCT01544465 |
|
|
45 |
Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia |
Withdrawn |
NCT03626727 |
Early Phase 1 |
Sodium Oxybate Oral Solution [Xyrem] |
|